Parse Biosciences, the premier provider of easy-to-use, scalable single-cell sequencing solutions, announced an agreement with INTEGRA Biosciences to combine Assist Plus with built-in Parse Evercode integrated single cell assay protocol. The scale of Parse technology combined with Assist Plus’ semi-automated liquid handling will significantly reduce hands-on time while further increasing workflow throughput and efficiency. Under the agreement, Parse will sell a bundled solution consisting of Evercode single-cell reagents and application-specific INTEGRA Assist Plus instruments directly to customers.
“INTEGRA Assist Plus will enable scientists to seamlessly analyze millions of cells per week and reduce hands-on time by up to 80%,” said Charlie Roco, co-founder and chief technology officer of Parse. He added: “Assist Plus is available on The first Parse products to be launched will be the Evercode Whole Transcriptome kit. We look forward to the development of this product and building a growing product library as applications and additional product support are added.”
The move supports Parse’s efforts to significantly expand the single-cell market by providing cost-effective, instrument-agnostic, easy-to-use single-cell sequencing solutions. Assist Plus is an easy-to-use instrument trusted by thousands of laboratories around the world. Parse customers will receive support from Parse Biosciences and INTEGRA’s field service and sales teams as part of the transaction.
Larry Keene, senior vice president of strategic sales at INTEGRA, said: “INTEGRA is pleased to partner with Parse to provide instrumentation, installation and training, and field service capabilities to provide Parse and Parse’s customers with reliable and rapid pre-sales and post-sales support.” He added “The cooperation between the two companies will bring tremendous value to Parse’s customers,” said Dao.
Parse Biosciences is a global biosciences company whose mission is to accelerate the advancement of human health and scientific research. The company helps researchers perform single-cell sequencing at unprecedented scale and convenience. Its groundbreaking methods have led to groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system.
SOURCE : BusinessWire